Precise And Efficient Editing Of The COL7A1 Gene In RDEB Derived iPSCs With CRISPR/Cas9 And Prime Editing

The study explores the use of CRISPR/Cas9 and prime editing technologies to correct mutations in the COL7A1 gene responsible for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe skin disorder. By reprogramming patient fibroblasts into induced pluripotent stem cells (iPSCs), which can be expanded and genetically modified, the researchers aim to produce a cell line with functional type VII collagen (C7). This approach addresses the limitations of CRISPR, such as low editing efficiency and off-target effects, by employing high fidelity Cas9 variants and prime editing. Whole genome CIRCLE-seq analysis identified 39 potential off-target sites, but preliminary results show no significant off-target activity. The strategy holds promise for creating iPSC lines that can be differentiated into functional skin cells, offering a potential therapeutic solution for RDEB patients.